Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding of how to treat non-small cell lung cancer with various driver mutations. We’ve broken down some highlights from targeted therapy information presented at the meeting.
Many patients with non-small cell lung cancer rely on a class of treatments called immunotherapy to battle their cancer. The significant difference between immunotherapy and targeted therapy (the other main type of treatment that patients with NSCLC receive) is that no biomarker is used that can directly predict whether the immunotherapy will work. Because of this unpredictability, there is ongoing research to better understand which patients respond well to immunotherapy and if there is any way to predict their response...
People who are diagnosed with early stage (stage 1-2) non-small cell lung cancer are generally broken down into two groups: those who can receive surgery to remove their tumor(s) and those who cannot. For both groups, it is important to consider how other treatments like radiation, chemotherapy and immunotherapy play a role in their treatment plan. At ASCO 2022, we learned about the latest treatments or people diagnosed with early stage NSCLC.
One of our priorities, alongside many other ally organizations, is to ensure that people diagnosed with lung cancer receive optimal care regardless of their background, socioeconomic status, race or ethnicity. Collectively, we’re working to break down barriers to equitable cancer care, which was a hot topic at the 2022 American Society of Clinical Oncology Annual Meeting. Our team was on the ground to bring you the latest news on this front.
People diagnosed with small cell lung cancer have historically had limited treatment options—but researchers are working to change that. At the 2022 American Society of Clinical Oncology Annual Meeting, results from a few key studies were presented for the first time, offering hope for future SCLC treatment advancements.
THANK YOU TO OUR SPONSORS
About Us

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.
Contact Us

Email: info@go2foundation.org    |    HelpLine: 1-800-298-2436 (9-5 EDT)

Washington, DC
Phone: 202-463-2080

San Francisco Bay Area
Phone: 650-598-2857